Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies

OBJECTIVE: Depressive symptoms are common in schizophrenia and can worsen outcomes and increase suicide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar I disorder. This post ho...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CNS Spectr
Egile Nagusiak: Nasrallah, Henry A., Cucchiaro, Josephine B., Mao, Yongcai, Pikalov, Andrei A., Loebel, Antony D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cambridge University Press 2014
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4411643/
https://ncbi.nlm.nih.gov/pubmed/24955752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S1092852914000285
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak